Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
04 juin 2021 09h00 HE
|
Provectus Biopharmaceuticals Inc.
— Systemic disease control achieved in heavily pre-treated liver cancer patients — 83% DCR; median PFS of 9.2 months; median OS of 22.5 months; half of patients undergoing response...